# Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

> **NCT00701298** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** peginterferon alfa-2b
- **DRUG:** decitabine
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00701298
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2010-10
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00701298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00701298, "Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00701298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*